阿托伐汀对急性冠状动脉综合征患者血清可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1的影响--附68例检测结果分析

目的:观察早期应用阿托伐汀对急性冠状动脉综合征患者的可溶性细胞间黏附分子-1(soluble intercellular adhesion molecules-1,sICAM-1)和可溶性血管细胞黏附分子-1(soluble vascularcell adhesion molecules-1,sVCAM-1)的影响,探讨阿托伐汀降低急性冠状动脉综合征炎症反应的可能机制.方法:稳定型心绞痛30例,急性冠状动脉综合征68例,后者再分为两亚组:阿托伐汀组35例,非阿托伐汀组33例.用酶联免疫吸附法测定急性冠状动脉综合征患者入院后第1、3、5、7、14日的sICAM-1和sVCAM-1水平,观察阿托伐汀对其sICAM-1和sVCAM-1水平的影响.结果:急性冠状动脉综合征患者入院时血清sICAM-1和sVCAM-1水平均比稳定型心绞痛组明显增高(P＜0.01).治疗后急性冠状动脉综合征两亚组的血清sICAM-1和sVCAM-1水平均有不同程度的降低,其中阿托伐汀组的下降更显著.结论:阿托伐汀可以降低炎症反应,在急性冠状动脉综合征的早期治疗中起重要作用.

Influence of atorvastatin on soluble intercellular adhesion molecules-1 and soluble vascular cell adhesion molecules-1 in paitents with acute coronary syndrome

Objective: To observe the influence of atorvastatin on so lu ble intercellular adhesion molecules-1(sICAM-1)and soluble vascular cell adhes ion molecules-1 (sVCAM-1) in patients with acute coronary syndrome(ACS),to pro be the mechanism of atorvastatin in lowering inflammatory reaction in patients w ith acute coronary syndrome. Methods: Patients were divided into tw o groups:30 patients with stable angina pectoris(SAP),68 patients with ACS. The latter group were divided into two sub-groups randomly: atorvastatin group and non-atorvastatin group. Serum concentrations of sICAM-1 and sVCAM-1 in pati ents with ACS were mea-sured by enzyme-linked immunosorbentassay(ELISA) on da y 1,3,5,7 and 14 after hospitalization. Results: Serum concentratio ns of sICAM-1 and sVCAM-1 in patients with ACS were higher than of SAP group ( P<0.01).In two sub-groups of ACS group, serum concentrations of sICAM-1 and sVCAM-1 in atorvastatin group decreased more significantly than th e other. Conclusion: Atorvastatin may decrease inflammatory reactio n and play a pivotal role in early therapy of ACS patients. [